Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease: Current State and Future Perspectives
Main Article Content
ABSTRACT
Alzheimer’s disease is the most common irreversible neurodegenerative disorder. To date, there is no cure for Alzheimer’s disease. While multiple pathological mechanisms have been proposed for the onset and progression of Alzheimer’s disease, the hypothesis that attracted much attention is the amyloid hypothesis. The senile plaques that accumulate in the brain of Alzheimer’s disease patients are predominantly composed of beta amyloid (Aβ). Aβ deposition in the brain is thought to occur years before the emergence of clinical symptoms. The overproduction, aggregation, and fibrillation of Aβ, combined with reduced clearance, eventually lead to amyloid plaque formation and subsequent neurotoxicity. Hence, inhibition of Aβ aggregation and the promotion of Aβ clearance have been actively explored as therapeutic strategies for Alzheimer’s disease. This chapter provides an overview of the current knowledge on one such strategy, Aβ-targeted inhibitory peptides.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.